RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Rhabdomyosarcoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
PAX3::FOXO1 and the INO80 complex sustain replication fork progression in fusion positive rhabdomyosarcoma.
Sahu Pushpendra Kumar et al., Molecular cancer research : MCR (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42873608/
- 2.
Novel mutations in nicotinamide phosphoribosyltransferase (NAMPT) arising from OT-82 exposure drive resistance in rhabdomyosarcoma (RMS) models
Ariana E. Nelson1, Abantika Chakraborty1, David R. Bell2, Victor J. Collins1, Ali Mokhtar Mahmoud1, Ying Wu2, Sophia Varriano1, Arnulfo Mendoza1, Sameer H. Issaq1, Parthav Jailwala2, Jack F. Shern1, Ernesto Suárez2, Joseph Ivanic2, Christine M. Heske1., Brown Digital Repository (13 October 2026)
https://doi.org/10.26300/vcmv-1g98
- 3.
Elevated FN14 expression promotes proliferation, chemoresistance, and impairment of differentiation in rhabdomyosarcoma.
Vuong Anh Tuan et al., Cancer letters (10 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42521076/
- 4.
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[
Mercolini Federico et al., Journal of clinical oncology : official journal of the American Society of Clinical Oncology (10 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42636421/
- 5.
Dose-effect analysis of late dental adverse effects following radiation therapy in survivors of paediatric head and neck rhabdomyosarcoma.
Krommenhoek Koen B et al., Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (10 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42858853/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585 · Recruiting · Phase 3 · Children's Oncology Group
Up to age 21
https://clinicaltrials.gov/study/NCT05304585
- 2.
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907 · Recruiting · Phase 1 / Phase 2 · University of Birmingham
https://clinicaltrials.gov/study/NCT04625907
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Rhabdomyosarcoma
Rhabdomyosarcoma is a rare cancer of the soft tissues that arises from cells which would normally develop into skeletal muscle. It is most often diagnosed in children and young people, and can start almost anywhere in the body, including the head and neck, urinary and reproductive organs, and the limbs. Treatment usually combines chemotherapy with surgery and radiotherapy, planned by a specialist sarcoma team.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Transcription factor fusions are recurrent drivers of sarcomas and other cancers, but their oncogenic reorganization of chromatin is difficult to target. One such fusion, PAX3::FOXO1, drives an aggressive subset of pediatric rhabdomyosarcoma (RMS) through chromatin remodeling, blocking terminal differentiation and sustaining proliferation. We hypothesized that identifying PAX3::FOXO1 genetic dependencies would reveal new facets of transcription factor fusion biology. We report an unexpected role for PAX3::FOXO1 in driving DNA replication fork progression, uncovered by its dependence on the INO80 chromatin remodeling complex (INO80c). Loss of the INO80c member UCHL5 reduces the competitive fitness of fusion positive (FP), but not fusion negative (FN) RMS cell lines, and is accompanied by reduced DNA replication fork speed. UCHL5 is required to maintain the N-terminal subdomain of INO80c, but a catalytically dead UCHL5 is sufficient to rescue complex formation, fork progression, and FP-RMS fitness. Similarly, loss of PAX3::FOXO1 rapidly leads to RPA32 foci and slows DNA fork progression. These findings demonstrate that PAX3::FOXO1 and INO80c are each critical to maintain replication fork progression in FP-RMS, a novel function for this transcription factor fusion. Implications: PAX3::FOXO1 and the N-terminal INO80 complex are both required to drive replication fork progression in FP-RMS, offering a counterpoint to models in which fusion oncogenes drive replication stress, and identifying INO80 complex members as a genetic dependency in FP-RMS cells.
Common Questions
What is Rhabdomyosarcoma?
Rhabdomyosarcoma is a rare cancer of the soft tissues that arises from cells which would normally develop into skeletal muscle. It is most often diagnosed in children and young people, and can start almost anywhere in the body, including the head and neck, urinary and reproductive organs, and the limbs. Treatment usually combines chemotherapy with surgery and radiotherapy, planned by a specialist sarcoma team.
How many clinical trials are available for Rhabdomyosarcoma?
RareWays currently indexes 207 clinical trials for Rhabdomyosarcoma, of which 38 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Rhabdomyosarcoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Rhabdomyosarcoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.